Opinion
Video
The panelists highlight key takeaways for payors involved in MDS treatment.
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Lack of CD20 Expression Worsens Outcomes for Bispecifics in R/R DLBCL
Five Years Later: Ongoing COVID-19 Challenges, Next Steps
Medicare Inflation Rebates Show Limited Impact on Drug Price Trends
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
HALP Score Acts as Prognostic Biomarker for Survival Outcomes in NSCLC
Obe-Cel Is Effective Irrespective of Age in Relapsed/Refractory B-ALL